Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MA HUANG EXEMPTION FROM DEA EPHEDRINE REGULATION

This article was originally published in The Tan Sheet

Executive Summary

MA HUANG EXEMPTION FROM DEA EPHEDRINE REGULATION based on the herbal's status as a dietary supplement has been requested by the New York law firm Bass & Ullman on behalf of BDI Pharmaceuticals and Valley Run Pharmaceuticals. In a Dec. 9 letter to the Drug Enforcement Administration, Bass & Ullman argued that the agency's "authority is limited to drug products containing ephedrine and does not extend to dietary supplements of Ma Huang because such products are not 'drugs' under the" FD&C Act.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS083557

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel